PEG-MGF

Pegylated form of Mechano Growth Factor (IGF-1Ec) - a splice variant of IGF-1 naturally produced in muscle tissue in response to mechanical stress. The PEG extension shifts half-life from minutes to days, enabling systemic use - at the cost of the local pulsatile architecture native MGF uses.

Research chemicalWADA S2 prohibitedInjectableIGF-1 isoform

Key facts

Common routesSC

Half-life48–72 hours

Typical range200–400 mcg 2x/week

Summary

PEG-MGF is a pegylated version of Mechano Growth Factor - a splice variant of IGF-1 (technically IGF-1Ec) produced naturally in muscle tissue in response to mechanical stress. Natural MGF has a very short half-life (minutes) and acts locally on satellite cells. The polyethylene glycol extension extends the half-life to days, enabling twice- or thrice-weekly systemic dosing.

The trade-off is real: pegylated MGF reaches more tissue systemically than natural pulsatile local signalling, but the natural architecture was pulsatile for a reason. Whether systemic PEG-MGF recreates the satellite-cell activation effect of native MGF or does something different-but-related is an open question. Use is bodybuilding-targeted at lagging muscle groups.

Mechanism notes

Satellite cell activation

MGF activates quiescent muscle satellite cells (stem cells) - a crucial first step in muscle repair and hypertrophy. Creates new myonuclei that support long-term growth potential.

ERK/MAPK signalling

Activates the ERK/MAPK pathway to drive proliferation of myoblasts (muscle precursor cells). Expands the muscle cell population before differentiation occurs.

Neuroprotection

MGF has been shown to prevent neuronal attrition and preserve function in ischaemic models. Potential secondary benefit for nerve health; less relevant for pure bodybuilding use.

Dosing patterns

Bodybuilding hypertrophy

200–400 mcg SC twice weekly (typically post-workout, into the targeted muscle). The longer half-life enables this cadence; don't dose more often as receptor saturation and IGF-1-system load scale.

Local (site-specific) use

Some operators inject into the target muscle post-workout for theoretical local-concentration advantage. Mechanistically defensible, but the PEG extension diffuses the signal more systemically than the natural short half-life would allow - the local advantage is limited.

Cycling discipline

4–8 week cycles with equal washout. PEG-MGF is growth-factor class - the cumulative-exposure risk frame from the IGF-1 LR3 world applies. Don't run year-round.

Evidence snapshot

Tier: Preclinical. Native MGF mechanism is well-established (Goldspink series), but the pegylated version is a grey-market innovation without human clinical trials specific to PEG-MGF. Anecdotal body-comp reports are real but tied to bodybuilding-stack context.

Animal / in vitro data

Goldspink et al. documented MGF as a key repair signal in muscle following mechanical stress. Animal data shows satellite-cell activation and myoblast proliferation. PEG variant: extrapolated from IGF-1 PEG-extension logic, not specifically validated.

Human data

No published human clinical trials for PEG-MGF specifically. Community logs are the only human signal - mixed, often in the context of AAS and other growth factors.

Safety considerations

Same growth-factor risk family as IGF-1 LR3 but with lower hypoglycaemia risk because MGF doesn't act centrally on the insulin receptor. Main concerns are cumulative growth-pathway load, theoretical tumour-promotion risk in pre-existing malignancies, and sourcing - PEG-MGF is non-standard synthesis and frequently mis-made.

Common cautions

Theoretical tumour-promotion risk in pre-existing malignancies - growth-factor class
Cycling discipline not optional - cumulative exposure matters more than per-cycle dose
Frequently mis-made in the grey market; PEG-extension quality is hard to verify without mass spectrometry
WADA S2 prohibited - growth factor category, banned at all times